Spinal cord series and cases · 2026
Retrospective safety evaluation of the atalante exoskeleton in a clinical setting in patients with tetraplegia and high paraplegia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Previnaire Jean-Gabriel, Baillet Héloise, Bel Jean-François, Péan Vincent, Cuenot Céline
Аннотация
STUDY DESIGN: Retrospective study.
OBJECTIVES: To evaluate the safety of the Atalante exoskeleton in patients with tetraplegia and high paraplegia.
SETTING: Three inpatient rehabilitation centers in France.
METHODS: Data from thirty-three inpatients with tetraplegia (12 motor complete (American Spinal Injury Association Impairment Scale (AIS) grade A or B), 10 motor incomplete (AIS C or D)) and high paraplegia (at or above T4 level; 10 motor complete and 1 motor incomplete) and an average time since Spinal Cord Injury (SCI) of 2.6 years (19 individuals < 12 months after injury), who completed at least one session of training with the Atalante exoskeleton, were analyzed. The primary outcome was the safety assessment through reported device-related adverse effects (AE). Secondary outcomes included pain (Numeric Pain Rating Scale), spasticity (Ashworth scale), walking ability (WISCI-II), and exoskeleton session data.
RESULTS: Participants underwent a median of 7.5 (IQR: 3-22.8) exoskeleton training sessions, with a median verticalization duration of 22.4 min (IQR: 18-26.9) and 583.0 steps (IQR: 347.0-854.0) performed. The estimated rate of AEs per session across all sessions was 0.63%, with a 95% confidence interval ranging from -0.56 to 1.81%. One minor AE occurred in one patient, involving hypotension, fatigue and dizziness, leading to session discontinuation. No therapy-related pain or fracture was reported. Regarding secondary outcomes, spasticity remained unchanged while positive changes were observed in WISCI-II scores in 11 patients with incomplete SCI.
CONCLUSIONS: After individual benefit-risk assessment, the Atalante exoskeleton can be safely used in a clinical setting for high SCI patients.
SPONSORSHIP: Wandercraft.
OBJECTIVES: To evaluate the safety of the Atalante exoskeleton in patients with tetraplegia and high paraplegia.
SETTING: Three inpatient rehabilitation centers in France.
METHODS: Data from thirty-three inpatients with tetraplegia (12 motor complete (American Spinal Injury Association Impairment Scale (AIS) grade A or B), 10 motor incomplete (AIS C or D)) and high paraplegia (at or above T4 level; 10 motor complete and 1 motor incomplete) and an average time since Spinal Cord Injury (SCI) of 2.6 years (19 individuals < 12 months after injury), who completed at least one session of training with the Atalante exoskeleton, were analyzed. The primary outcome was the safety assessment through reported device-related adverse effects (AE). Secondary outcomes included pain (Numeric Pain Rating Scale), spasticity (Ashworth scale), walking ability (WISCI-II), and exoskeleton session data.
RESULTS: Participants underwent a median of 7.5 (IQR: 3-22.8) exoskeleton training sessions, with a median verticalization duration of 22.4 min (IQR: 18-26.9) and 583.0 steps (IQR: 347.0-854.0) performed. The estimated rate of AEs per session across all sessions was 0.63%, with a 95% confidence interval ranging from -0.56 to 1.81%. One minor AE occurred in one patient, involving hypotension, fatigue and dizziness, leading to session discontinuation. No therapy-related pain or fracture was reported. Regarding secondary outcomes, spasticity remained unchanged while positive changes were observed in WISCI-II scores in 11 patients with incomplete SCI.
CONCLUSIONS: After individual benefit-risk assessment, the Atalante exoskeleton can be safely used in a clinical setting for high SCI patients.
SPONSORSHIP: Wandercraft.